NHS Wegovy Cardiovascular Expansion: New Access for Heart Risk Reduction
From April 2026, the NHS in England has expanded access to Wegovy (semaglutide 2.4mg) for a new indication: cardiovascular risk reduction. This is separate from the existing weight management pathway. You no longer need to meet standard obesity BMI thresholds if you have established cardiovascular disease and meet the new criteria.
This is a significant policy shift backed by strong trial data.
What Changed
Previously, NHS Wegovy was available only through Tier 3 weight management services, requiring BMI of 35 or above (with comorbidity) or 30 or above (with specialist referral). The pathway was slow, with waiting lists of 6 to 18 months.
From April 2026:
- Wegovy is now available through cardiology and primary care pathways for cardiovascular risk reduction
- Eligibility is based on cardiovascular history, not just BMI
- GPs can initiate prescriptions without Tier 3 weight management referral for qualifying patients
- NICE Technology Appraisal TA1042 underpins the new access route
The SELECT Trial: Why This Happened
The expansion is driven by the SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity), the largest cardiovascular outcomes trial for a GLP-1 receptor agonist in non-diabetic patients.
Trial Design
- Enrolled: 17,604 adults aged 45 and over
- Population: Overweight or obese (BMI 27+), with established cardiovascular disease (prior heart attack, stroke, or peripheral arterial disease)
- Excluded: Type 2 diabetes (this was specifically a non-diabetic population)
- Treatment: Semaglutide 2.4mg weekly vs placebo
- Duration: Median follow-up 39.8 months (over 3 years)
- Primary endpoint: Major adverse cardiovascular events (MACE) - cardiovascular death, non-fatal heart attack, non-fatal stroke
Key Results
| Outcome | Semaglutide 2.4mg | Placebo | Reduction | |---------|-------------------|---------|-----------| | MACE (primary composite) | 6.5% | 8.0% | 20% relative risk reduction | | Cardiovascular death | 2.5% | 3.0% | 15% reduction | | Non-fatal heart attack | 2.6% | 3.5% | 28% reduction | | Non-fatal stroke | 1.7% | 2.0% | 7% reduction | | All-cause mortality | 4.3% | 4.9% | 13% reduction |
What This Means in Plain English
For every 1,000 patients treated with semaglutide 2.4mg for 3 years (compared to placebo):
- 15 fewer major cardiovascular events (heart attacks, strokes, cardiovascular deaths)
- 8 fewer heart attacks
- 6 fewer cardiovascular deaths
The number needed to treat (NNT) is approximately 67 for 3 years to prevent one MACE event. In cardiovascular medicine, this is considered clinically meaningful and compares favourably with established secondary prevention treatments.
Beyond Weight Loss
The cardiovascular benefit was not fully explained by weight loss alone. Semaglutide appears to have direct cardiovascular protective effects:
- Reduced systemic inflammation (C-reactive protein decreased by 37%)
- Improved lipid profile (LDL reduced, HDL improved)
- Reduced blood pressure (average 3.5mmHg systolic reduction)
- Improved endothelial function
- Reduced arterial stiffness
This is why the cardiovascular indication is separate from the obesity indication. Even patients who do not lose substantial weight may benefit from the cardiovascular protection.
New Eligibility Criteria
Who Qualifies Under the Cardiovascular Pathway
You may be eligible if you meet ALL of the following:
1. Established cardiovascular disease:
- Previous myocardial infarction (heart attack)
- Previous stroke or transient ischaemic attack (TIA)
- Confirmed peripheral arterial disease
- Previous coronary revascularisation (stent or bypass)
- Confirmed atherosclerotic cardiovascular disease on imaging
2. Overweight or obese:
- BMI 27 or above (note: lower threshold than the weight management pathway)
3. Not diabetic:
- No current diagnosis of type 2 diabetes
- Patients with type 2 diabetes have separate GLP-1 pathways through diabetes services
4. Age:
- 45 years and over (consistent with SELECT trial population)
Who Does Not Qualify
- BMI below 27
- No established cardiovascular disease (even with risk factors alone)
- Current type 2 diabetes diagnosis (separate pathway exists)
- Under 45 years old
- History of medullary thyroid carcinoma or MEN 2
- History of pancreatitis
- Pregnancy or planning pregnancy
Important Distinctions
Cardiovascular risk factors alone are not sufficient. You need established disease (a previous event or confirmed atherosclerosis), not just risk factors like hypertension or high cholesterol.
HbA1c in the prediabetic range (42 to 47 mmol/mol) does not exclude you, provided you do not have a formal type 2 diabetes diagnosis.
How to Access Through Your GP
Step-by-Step Process
1. Book a GP appointment Contact your surgery and request an appointment to discuss cardiovascular risk management and Wegovy eligibility.
2. Bring your cardiovascular history Your GP will need to confirm:
- Date and type of previous cardiovascular event(s)
- Current medications (statins, antihypertensives, antiplatelets)
- Recent blood results (lipids, HbA1c, renal function)
- Current BMI
3. GP assessment Your GP will:
- Verify you meet the NICE TA1042 criteria
- Check for contraindications
- Review your current medications for interactions
- Calculate your current cardiovascular risk score
4. Prescription initiation If eligible, your GP can initiate Wegovy directly. Unlike the weight management pathway, this does not require a Tier 3 referral.
5. Titration Standard Wegovy titration applies:
- 0.25mg for 4 weeks
- 0.5mg for 4 weeks
- 1.0mg for 4 weeks
- 1.7mg for 4 weeks
- 2.4mg maintenance dose
6. Monitoring
- Monthly reviews for the first 3 months
- Quarterly reviews thereafter
- Annual cardiovascular risk reassessment
- Regular blood tests (lipids, HbA1c, renal function)
What to Say to Your GP
GPs are still becoming familiar with this new pathway. If your GP is unsure, you can reference:
- NICE TA1042 (the specific technology appraisal)
- The SELECT trial (the evidence base)
- NHS England commissioning guidance for semaglutide cardiovascular indication
Some GPs may want to discuss with their local cardiology team before prescribing. This is reasonable and shows good clinical governance.
If Your GP Is Not Familiar with the Pathway
This is a new indication and some GP surgeries may not yet have updated prescribing protocols. If this happens:
- Ask your GP to check the NICE website for TA1042
- Request a referral to your local cardiology team for assessment
- Contact your local Integrated Care Board (ICB) to confirm the pathway is commissioned in your area
Regional Availability
England
- Available from April 2026 in most ICB areas
- Some ICBs may have a phased rollout
- Contact your ICB to confirm local availability
Scotland
- NHS Scotland is reviewing the SELECT trial data
- Expected to follow England's lead, but timeline uncertain
- Check with your Health Board
Wales
- AWMSG (All Wales Medicines Strategy Group) reviewing
- Not yet available as of April 2026
- Expected decision by late 2026
Northern Ireland
- Under review
- Private clinics remain the primary access route for now
How This Differs from the Weight Management Pathway
| Factor | Weight Management Pathway | Cardiovascular Pathway | |--------|--------------------------|----------------------| | BMI threshold | 35+ (or 30+ with comorbidity) | 27+ | | Requires CV disease | No | Yes (established) | | Age requirement | None specified | 45+ | | Referral needed | Tier 3 weight management | GP can initiate directly | | Waiting list | 6 to 18 months | Weeks (GP appointment) | | Primary goal | Weight reduction | Cardiovascular risk reduction | | Duration | 12-month cycles with review | Ongoing (no defined end point) | | Monitoring | Weight management service | GP with cardiology input |
The cardiovascular pathway is faster to access because it bypasses the weight management service bottleneck.
Cost
NHS: Free. Fully funded under NICE TA1042.
If accessing privately while waiting: Private Wegovy costs £180 to 250 per month. You can transition to NHS once the GP pathway is set up.
Combining with Existing Medications
Most cardiovascular patients are already on multiple medications. Semaglutide has no major drug interactions with standard cardiovascular drugs:
- Statins: No interaction. Continue as prescribed.
- Antihypertensives (ACE inhibitors, ARBs, beta-blockers, calcium channel blockers): No interaction. Blood pressure may improve, so monitoring is important. Your GP may reduce antihypertensive doses over time.
- Antiplatelets (aspirin, clopidogrel): No interaction.
- Anticoagulants (warfarin, DOACs): No significant interaction, though delayed gastric emptying may theoretically affect absorption. INR monitoring recommended if on warfarin.
- Metformin: If you develop type 2 diabetes while on semaglutide, metformin can be added safely.
Note: Semaglutide slows gastric emptying, which can delay absorption of some oral medications. Take time-sensitive medications (levothyroxine, for example) at least 1 hour before or after your injection day meal.
Frequently Asked Questions
Q: I had a heart attack 5 years ago. Am I eligible? Yes, provided your BMI is 27+ and you are 45 or over. There is no time limit on when the cardiovascular event occurred.
Q: I have high blood pressure but no heart attack or stroke. Do I qualify? No. The cardiovascular pathway requires established cardiovascular disease (a previous event or confirmed atherosclerosis), not just risk factors.
Q: I am already on Wegovy through the weight management pathway. Does this change anything? If you also have established cardiovascular disease, your prescribing rationale may be updated. Practically, the medication and dose remain the same. The benefit is that your treatment may continue beyond the standard 12-month weight management cycle.
Q: Can I get the 7.2mg dose through this pathway? Not yet. The cardiovascular indication is based on the SELECT trial, which used 2.4mg. The 7.2mg dose is currently only approved for weight management.
Q: I have type 2 diabetes and cardiovascular disease. Does this apply to me? No. Patients with type 2 diabetes have separate GLP-1 prescribing pathways through diabetes services. The cardiovascular expansion specifically applies to non-diabetic patients, consistent with the SELECT trial population.
Q: How long will I stay on Wegovy under this pathway? Indefinitely, subject to ongoing clinical review. Unlike the weight management pathway (12-month cycles), cardiovascular risk reduction is a long-term treatment goal. Stopping semaglutide would remove the cardiovascular protective effect.
Key Takeaway
The NHS cardiovascular expansion for Wegovy is a genuine step forward in preventive cardiology. If you have established cardiovascular disease, a BMI of 27 or above, and you are 45 or older, you may now qualify for free Wegovy through your GP without the long weight management waiting list.
The SELECT trial showed a 20% reduction in major cardiovascular events over 3 years. This is not a weight loss programme. It is secondary cardiovascular prevention, backed by one of the largest and most rigorous trials in the GLP-1 field.
Book a GP appointment and ask about NICE TA1042.
Next Steps
- NHS GLP-1 eligibility guide (weight management pathway)
- Wegovy vs Ozempic: UK differences
- Wegovy 7.2mg dose guide
- Managing GLP-1 side effects
- UK private GLP-1 clinics compared
As an Amazon Associate I earn from qualifying purchases.
Disclaimer: This is educational information, not medical advice. Cardiovascular risk management requires individualised clinical assessment. Always consult your GP or cardiologist before starting or changing medication.